Gut microbiota of HIV-infected patients with multidrug-resistant tuberculosis

Aim. To determine the composition and properties of the gut microbiota in HIV-infected patients with pulmonary tuberculosis.

Materials and Methods. We studied 92 faecal samples from patients with pulmonary tuberculosis (n = 46) and patients with combined pulmonary tuberculosis and HIV infection (n = 46), with the following examination of the appearance, cultural properties, and biochemical profile of the bacteria. The constancy of microbial taxa was determined using Dazho-Odum indicator. Microorganisms were classified as constant at C > 50%, as complementary at 25% < C < 50% and as occasional at C < 25%.

Results. Gut microbiota of patients with multidrug-resistant tuberculosis was consistently represented by Bifidobacterium spp., Lactobacillus spp., Enterococcus spp., Escherichia spp., Staphylococcus spp., and Candida regardless of their

HIV status. Species composition and prevalence of virulence factors in Staphylococcus spp. and fungi isolated from patients with multidrug-resistant tuberculosis also did not depend on HIV status. Complementary microorganisms were represented exclusively by Clostridium spp., while random microbiota was represented by 6 genera (Enterobacter spp., Citrobacter spp., Salmonella spp., Klebsiella spp., Proteus spp., and Pseudomonas spp.) belonging to the Proteobacteria phylum.

Conclusion. Similar composition of gut microbiota in HIV-positive and HIV-negative patients with multidrug-resistant tuberculosis indicates common mechanisms of intestinal dysbiosis and a uniform approach for its correction.

1. Wang B, Yao M, Ly L, Ling Z, Li L. The human microbiota in health and disease. Engineering. 2017;3:71-82. http://doi.org/10.1016/J. ENG.2017.01.008

2. Turroni F, Milani Ch, Ventura M, Sinderen D. The human gut microbiota during the initial stages of life: insights from Bifidobacteria. Curr Opin Biotechnol. 2022;73:81-87. https://doi.org/10.1016/j.copbio.2021.07.012

3. Ding RX, Goh WR, Wu RN, Yue XQ, Luo X, Khine WWT, Wu JR, Lee YK. Revisit gut microbiota and its impact on human health and disease. J Food Drug Anal. 2019;27(3):623-631. https://doi.org/10.1016/j.jfda.2018.12.012

4. Ivleva EA, Grivennikov SI. Microbiota-driven mechanisms at different stages of cancer development. Neoplasma. 2022;32:100829. https://doi.org/10.1016/j.neo.2022.10082

5. Zakharova YuV, Bykov AS, Nurtazina AYu, Markovskaya AA, Afanasyev SS, Nesvizh YuV, Afanasyev MS. Intestinal microbiocenosis at different stages of hiv infection in pediatric patients. Immunopathology, allergology, infectology. 2020;2:90-95. (In Russ). https://doi.org/10.14427/jipai.2020.2.90

6. Komarova MV, Kroider AS. The use of biological diversity indices for the analysis of human microbiota. Universum: Medicine and Pharmacology. 2022;3(86). (In Russ). Available at: https://7universum.com/ ru/med/archive/item/13192. Accessed: 26 November, 2021.

7. Kaibysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Human microbiome: age-related changes and functions. Evidence-based gastroenterology.2020;9(2):42-55. (In Russ). https://doi.org/10.17116/dokgastro2020902142

8. Sitkin SI, Tkachenko EI, Vakhitov TYa. Phylometabolic core of intestinal microbiota. Almanah of Clinical Medicine. 2015;40:12-34. (In Russ).

9. Wozniak D, Cichy W, Przyslawski J, Drzymala-Czuz S. The role of microbiota and enteroendocrine cells in maintaining homeostasis in the human digestive tract. Advances in medical sciences. 2021;66(2):284292. https://doi.org/10.1016/j.advms.2021.05.003

10. Kholodov AA, Zakharova YuV, Otdushkina LYu, Galaida NM, Pyanzova TV. Intestinal microbiocenosis in patients with multidrug-resistant pulmonary tb and intestinal dyspepsia syndrome due to tb treatment. Bulletin of the Central Research Institute of Tuberculosis. 2022;1:79-86. (In Russ). https://doi.org/10.7868/S2587667822010083

11. Rodina OV, Borisov SE, Ivanova DA. Adverse events of the new and traditional chemotherapy regimens in the patients with multi drug resistant pulmonary tuberculosis. Tuberculosis and socially significant diseases. 2020;2:44-54. (In Russ).

12. Belova IV, Barbolina SF, Tochilina AG, Soloveva IV, Shprykov AS, Ivanova TP, Zhirnov AV, Sherstnev IG, Vasilieva NV, Anikina OA. Prophylaxis of forming the expressed disorders of microbiocenosis of a large bowel in the case of patients having tuberculosis, including that with a multiple medicine resistance. Meditsinskiy al'manakh. 2016;43(3):112-117. (In Russ).

13. Klimenko AI, Mustafin ZS, Chekantsev AD, Zudin RK, Matushkin YuG, Lashin SA. A review of simulation and modeling approaches in microbiology. Vavilov Journal of Genetics and Breeding. 2015;19(6):745-752. (in Russ).

14. Erum R, Samad F, Khan A, Kazmi SU. A comparative study on production of extracellular hydrolytic enzymes of Candida species isolated from patients with surgical site infection and from healthy individuals and their corelation with antifungal drug resistance. BMC Microbiology. 2020;20(1):368. https://doi.org/10.1186/s12866-020-02045-6.

15. Solovyova I. V., Belova I. V., Tochilina A. G., Barbolina S. F., Ivanova T. P., Zhirnov V. A. Microbiota of the colon of patients with multidrug-resistant tuberculosis. Medical Academic Journal. 2017; 17(4): 71-73.

16. Ueckermann V, Lebre P, Geldenhuys J, Hoosien E, Cowan D, Rensburg L.J, Ehlers M. The lung microbiome in HIV-positive patients with active pulmonary tuberculosis. Scientifc Reports. 2022;12:8975. https://doi.org/10.1038/s41598-022-12970-3.